Andrea Harris

Health care investors are entering both the final stretch of 2018 and the final weeks of a GOP-controlled House of Representatives. Height Capital Markets analyst Andrea Harris surveyed nine potential health care catalysts that investors should be watching between now and the end of December...

Americans and investors have a lot riding on Tuesday’s midterm elections, but the health care industry in particular is hanging in the balance. On Monday, Height Capital Markets named four themes in the health care sector that will be shaped by the election outcome: A Democratic majority in...

The opioid epidemic is one of the most devastating trends in American households, with CDC data showing that 66 percent of the country's overdose deaths in 2016 were attributed to opioids. Unfortunately, Height Capital Markets analyst Andrea Harris said there’s not much hope...

President Donald Trump is keeping pharmaceutical execs, lobbyists and investors on their toes. But very few of the president’s tactics — not even Wednesday’s unexpected, offhand remark portending “voluntary massive drops in prices” in two weeks — surprise Height...

The Food and Drug Administration announced Monday it would publish correspondence with drug manufacturers accused of abusing agency standards to foil generic competitors. Height Capital Markets considers the public censuring indicative of a broader federal strategy to pressure industry change....

Congress introduced the Consolidated Appropriations Act of 2018 on Wednesday, and the bill contains fewer health care provisions than many traders expected. Still, Height Capital Markets analyst Andrea Harris said on Thursday there are several pharmaceuticals and managed care winners and losers...

Amazon.com, Inc. (NASDAQ: AMZN) confirmed its interest in the health care space earlier this year when it announced a health care partnership with J.P. Morgan Chase & Co. (NYSE: JPM) and Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B). The M&A environment in the health care space has...

Pharmaceutical manufacturers are lobbying to reverse Medicare Part D discounts before Congress passes its omnibus spending bill by March 23.  By Height Capital Markets’ assessment, the odds are marginally in big pharma's favor. The campaign-leading Pharmaceutical Research and...

The pharmaceutical industry is lobbying to reverse part of the recent Congressional spending bill that shifted a $10-billion consumer aid burden from the federal government to manufacturers. The Bipartisan Budget Act of 2018 accelerated the closure of the Medicare Part D coverage gap from 2020 to...

President Donald Trump's tax reform victory could positively impact the health care sector and fuel a new round of M&A activity, according to one analyst.  The Analyst Height Healthcare's Shrey Verma and Andrea Harris. The Thesis Corporate tax reform is expected to fuel health...